Moreover, this study shows that adenosine produced by GRHL2-depleted breast cancer cells (or provided as a stable analog) can augment the recruitment of CD8 T cells, in addition to its previously established role as a suppressor of T cell-mediated cytotoxicity. Here, GRHL2 is linked to breast carcinoma.